New data for Merck's antivomiting drug support label expansion; Brazil fines Lilly for 'sham' patent litigation;

@FiercePharma: ICYMI yesterday: Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say. Report | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: France's TxCell closes its plant at ANSM urging to avoid contamination. Article | Follow @EricPFierce

@CarlyHFierce: Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say. More | Follow @CarlyHFierce

> In a Phase III study, Merck's ($MRK) antivomiting drug for chemo patients, Emend, scored a statistically significant complete response rate among patients getting a moderately emetogenic (or vomit-inducing) chemotherapy. Story

> Brazilian authorities have fined Eli Lilly ($LLY) about $11 million for pursuing "sham" patent litigation. Report (sub. req.)

> India's Dr. Reddy's Laboratories ($RDY) is recalling two generic drugs from the U.S. market. More

> Menarini has won approval in Europe for an expanded indication for gout drug Adenuric. Release

> Pfizer Consumer Healthcare ($PFE) and Tris have inked a pact to market extended-release cough treatment Robitussin. More

> AMAG Pharmaceuticals ($AMAG) is buying the stem-cell storage company Cord Blood Registry for $700 million from private equity firm GTCR. More

> Bayer has submitted an application for its recombinant factor VIII hemophilia treatment in Japan. News

> AstraZeneca ($AZN) and the University of Cambridge have announced new joint PhD and clinical research scholarships. Release

Medical Device News

@FierceMedDev: UPDATED: Microchips Biotech partners with Teva on wireless drug delivery, announces new CEO, raises $18M in financing. FierceDrugDelivery story | Follow @FierceMedDev

@VarunSaxena2: FDA warns that transdermal patch for ADHD can lead to permanent skin discoloration. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: AdverseEvents flags TB reports, blood-disorder cases linked to RA drugs. FiercePharma report | Follow @EmilyWFierce

> Investors punish micro-cap EnteroMedics as it raises $35M to market recently approved obesity device. Report

> Startup gets CE mark for novel blood-draw tech after FDA clearance, Series A earlier this year. Story

> DOJ calls off investigation of Abiomed's Impella marketing. Article

Biotech News

@FierceBiotech: Biotech billionaire Soon-Shiong plots a second IPO for NantHealth. News | Follow @FierceBiotech

@JohnCFierce: Op-Ed: Is Celgene killing the traditional biotech partnering formula? More | Follow @JohnCFierce

@DamianFierce: $CELG is basically a microlending platform for oncology biotechs. More | Follow @DamianFierce

> Transgene is shedding 120 jobs to save cash and get its pipeline moving. Report

> Intercept files its 'breakthrough' liver drug for rare disease approval. Item

> Waksal's post-prison startup runs into more fraud allegations. Article

Drug Delivery News

> Cynapsus' sublingual Parkinson's med for levodopa nonresponders progresses to PhIII. Report

> Langer Lab company gets $5M in funding for drug-delivery device. Item

> OptiNose heralds late-stage clinical success for nasal anti-inflammatory. More

> Alnylam's hemophilia candidate reduces levels of anticoagulant in PhI study. Article

> FDA warns that transdermal patch for ADHD can lead to permanent skin discoloration. Story

Pharma Manufacturing News

> Capsugel completes $25M spray-dried expansion. Item

> India's Dr. Reddy's recalls 10 lots of two drugs that failed specifications. More

> Some Indian drugmakers see M&A preferable to investing in plant upgrades. Article

> Canada's Ropack buying Forest operations on Long Island. Story

> GSK doubles down on Singapore continuous processing plant. Report

Pharma Asia News

> Blurred lines in Japan's vision for healthcare in next two decades. Report

> Out with the old, reimburse the new: Merck's Frazier wades into Australia drug debate. More

> Troubled India's Wockhardt sees third U.S. drug recall in as many months. Report

> No artful tax dodging here, drug firms tell Australia transfer-price inquiry. Story

> Taiwan's PharmaEngine racks up good news on MM-398. Article

And Finally... Only about one in 8 pre-diabetic people know they have a problem, a new study shows. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.